Logo

Twist Bioscience RUO SARS-CoV-2 Antibody Panels

Jul 28, 2020

Twist Bioscience is offering two new SARS-CoV-2 antibody panels for research use only.

The Twist anti-SARS-CoV-2 S1 antibody panel includes 32s human antibodies that bind with picomolar to nanomolar affinity to the S1 spike protein of the virus that causes COVID-19. The Human anti-ACE2 panel includes 48 antibodies that bind to the extracellular domain of the ACE2 receptor on human cells, the protein that facilitates entry of the coronavirus into cells.

All antibodies are cloned into human antibody backbones to generate VHH Fc, IgG1, or IgG2 antibodies. Individual antibodies within the panel can be licensed for further therapeutic or diagnostic development.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.